The  report shows that although India has made some progress, it continues to have the highest disease burden.

• Tuberculosis is an infectious disease caused by bacteria (Mycobacterium tuberculosis) and most commonly affects lungs and is curable as well as preventable
• It spreads through the air when people with lung TB cough, sneeze or spit.

Key Findings of the Report

• In 2023, TB likely became the leading infectious killer globally, surpassing Covid-19.
• TB Treatment coverage: It  has increased to 75% as against target of 90% by 2027
• India specific findings
  • India accounted for 26% of the global TB burden in 2023 and  26% of global TB related deaths.
  • India ranks 1st globally in burden of multidrug resistant/Rifampicin-resistant TB

Issues highlighted by Report

• Inadequate funding  in low- and middle-income countries: It was merely US$ 5.7 billion(in 2023) equivalent to only 26% of the global target of reaching US$ 22 billion per year(2027).
  • Funding in TB Research: It was US $1 billion(2022) as against target of US$5 billion(2027)
• Catastrophic health costs (>20% of annual household income):  Around 50%  of the TB-affected households globally face catastrophic costs, far above the WHO End TB Strategy target of zero.